- Home
- SNX vs BBIO Comparison
SNX vs BBIO Comparison
Compare SNX & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNX
- BBIO
- Stock Information
- Founded
- SNX 1980
- BBIO 2015
- Country
- SNX United States
- BBIO United States
- Employees
- SNX N/A
- BBIO N/A
- Industry
- SNX Retail: Computer Software & Peripheral Equipment
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- SNX Technology
- BBIO Health Care
- Exchange
- SNX Nasdaq
- BBIO Nasdaq
- Market Cap
- SNX 10.6B
- BBIO 8.0B
- IPO Year
- SNX 2003
- BBIO 2019
- Fundamental
- Price
- SNX $135.82
- BBIO $42.78
- Analyst Decision
- SNX Strong Buy
- BBIO Strong Buy
- Analyst Count
- SNX 9
- BBIO 14
- Target Price
- SNX $140.89
- BBIO $58.85
- AVG Volume (30 Days)
- SNX 995.4K
- BBIO 3.3M
- Earning Date
- SNX 06-24-2025
- BBIO 07-31-2025
- Dividend Yield
- SNX 1.30%
- BBIO N/A
- EPS Growth
- SNX 19.95
- BBIO N/A
- EPS
- SNX 8.56
- BBIO N/A
- Revenue
- SNX $60,007,297,000.00
- BBIO $127,415,000.00
- Revenue This Year
- SNX $3.34
- BBIO $102.05
- Revenue Next Year
- SNX $4.55
- BBIO $54.69
- P/E Ratio
- SNX $15.81
- BBIO N/A
- Revenue Growth
- SNX 6.60
- BBIO N/A
- 52 Week Low
- SNX $92.23
- BBIO $21.72
- 52 Week High
- SNX $145.10
- BBIO $45.48
- Technical
- Relative Strength Index (RSI)
- SNX 68.15
- BBIO 62.54
- Support Level
- SNX $133.71
- BBIO $39.65
- Resistance Level
- SNX $138.97
- BBIO $45.48
- Average True Range (ATR)
- SNX 3.29
- BBIO 1.56
- MACD
- SNX 0.78
- BBIO 0.15
- Stochastic Oscillator
- SNX 80.31
- BBIO 60.90
About SNX TD SYNNEX Corporation
TD Synnex Corp is a distributor and solutions aggregator for the IT ecosystem. The company aggregates and distributes IT hardware, software, and systems including personal computing devices and peripherals, mobile phones and accessories, printers, server and data center infrastructure, hybrid cloud, security, networking, communications and storage solutions, and system components. Its geographical segments include the Americas, Europe, and APJ.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.